Entry Point Capital, LLC Rapt Therapeutics, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RAPT
# of Institutions
125Shares Held
29.1MCall Options Held
905KPut Options Held
592K-
Vanguard Group Inc Valley Forge, PA3.11MShares$5.69 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$4.91 Million11.48% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$4.46 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$3.16 Million0.61% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$2.93 Million52.54% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $54.3M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...